Development of an Ophthalmic Hydrogel to Deliver MG53 and Promote Corneal Wound Healing
Pharmaceutics · 16.04.2025 · 17 (4) · 526
DOI: 10.3390/pharmaceutics17040526 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 16.04.2025. Verfasst von Heather L Chandler und 10 weiteren Autor:innen. Beteiligte Einrichtung: College of Optometry, The Ohio State University, Columbus, OH 43210, USA. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NEI NIH HHS, NIH HHS, NIBIB NIH HHS.
Themen: Wundversorgung
Abstract (Originalsprache)
Background/Objective: A clinical need exists for more effective therapeutics and sustained drug delivery systems to promote ocular surface healing. This study tested the hypothesis that a novel biodegradable, thermoresponsive hydrogel loaded with the human recombinant (rh)MG53 protein, which we have demonstrated to promote corneal healing without fibrosis, would exhibit safety and biocompatibility in vitro and in vivo.
Methods
Hydrogel optimization was performed based on varying concentrations of poloxamer 407, poloxamer 188, and hydroxypropyl methylcellulose. Hydrogels were characterized and potential toxicity was evaluated in vitro in cultured corneal epithelium, fibroblasts, and endothelium. In vivo safety and tolerability were assessed in mice and hydrogels were used to evaluate corneal healing following alkali injury.
Results
The optimized hydrogel formulation did not result in any detrimental changes to the corneal cells and released functional rhMG53 protein for at least 24 h. In vivo rhMG53-loaded hydrogels improved re-epithelialization, reduced stromal opacification and vascularization, and promoted corneal nerve density. Mechanistically, rhMG53 reduced vascular endothelial cell migration and tube formation by inhibiting pSTAT3 signaling.
Conclusions
Taken together, our poloxamer-based thermoresponsive hydrogel effectively released rhMG53 protein and enhanced multiple corneal healing outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- College of Optometry, The Ohio State University, Columbus, OH 43210, USA.
- Department of Biomedical Engineering, The Ohio State University, Columbus, OH 43210, USA.
- Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA.
- Division of Surgical Sciences, Department of Surgery, University of Virginia Medical School, Charlottesville, VA 22903, USA.
ORCID-Profile: Heather L Chandler, Sara Moradi, Luxi Zhang, Zhentao Zhang, Hua Zhu, Katelyn E Swindle-Reilly
Förderung
- NEI NIH HHS
- NIH HHS
- NIBIB NIH HHS
- National Eye Institute, National Institutes of Health
- Owen Locke Foundation
- Ohio State University, College of Engineering
Zitieren
APA
Chandler, H. L., Moradi, S., Green, S. W., Chen, P., Madden, C., Zhang, L., Zhang, Z., Park, K. H., Ma, J., Zhu, H., & Swindle-Reilly, K. E. (2025). Development of an Ophthalmic Hydrogel to Deliver MG53 and Promote Corneal Wound Healing. Pharmaceutics, 17(4), 526. https://doi.org/10.3390/pharmaceutics17040526
Vancouver
Chandler HL, Moradi S, Green SW, Chen P, Madden C, Zhang L, et al. Development of an Ophthalmic Hydrogel to Deliver MG53 and Promote Corneal Wound Healing. Pharmaceutics. 2025;17(4):526. doi:10.3390/pharmaceutics17040526
BibTeX
@article{Chandler2025,
author = {Chandler, Heather L and Moradi, Sara and Green, Spencer W and Chen, Peng and Madden, Christopher and Zhang, Luxi and Zhang, Zhentao and Park, Ki Ho and Ma, Jianjie and Zhu, Hua and Swindle-Reilly, Katelyn E},
title = {Development of an Ophthalmic Hydrogel to Deliver MG53 and Promote Corneal Wound Healing},
journal = {Pharmaceutics},
year = {2025},
volume = {17},
number = {4},
pages = {526},
doi = {10.3390/pharmaceutics17040526}
}
EUVIMED